The Experts below are selected from a list of 4581 Experts worldwide ranked by ideXlab platform
David Petroff - One of the best experts on this subject based on the ideXlab platform.
-
design of the weight loss endoscopy trial wet a multi center randomized controlled trial comparing weight loss in Endoscopically implanted duodenal jejunal bypass liners vs intragastric balloons vs a sham procedure
BMC Gastroenterology, 2018Co-Authors: M Hollenbach, Christiane Prettin, F Gundling, W Schepp, Jochen Seufert, Jurgen Stein, Thomas Rosch, Jens Aberle, Jurgen Feisthammel, David PetroffAbstract:Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive Endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these Devices has not been undertaken or shown to be superior to a sham procedure. We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in Endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the Devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the Devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated. This trial could help to identify the most effective and safest Endoscopic Device, thus determining the new standard procedure for Endoscopic bariatric treatment. 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).
M Hollenbach - One of the best experts on this subject based on the ideXlab platform.
-
design of the weight loss endoscopy trial wet a multi center randomized controlled trial comparing weight loss in Endoscopically implanted duodenal jejunal bypass liners vs intragastric balloons vs a sham procedure
BMC Gastroenterology, 2018Co-Authors: M Hollenbach, Christiane Prettin, F Gundling, W Schepp, Jochen Seufert, Jurgen Stein, Thomas Rosch, Jens Aberle, Jurgen Feisthammel, David PetroffAbstract:Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive Endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these Devices has not been undertaken or shown to be superior to a sham procedure. We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in Endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the Devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the Devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated. This trial could help to identify the most effective and safest Endoscopic Device, thus determining the new standard procedure for Endoscopic bariatric treatment. 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).
Frits J Berends - One of the best experts on this subject based on the ideXlab platform.
-
changes in glycemic control and body weight after explantation of the duodenal jejunal bypass liner
Gastrointestinal Endoscopy, 2017Co-Authors: Bark Betzel, Parviez Koehestanie, Jens Homan, Edo O Aarts, Ignace M C Janssen, Hans De Boer, Peter J Wahab, Marcel J M Groenen, Frits J BerendsAbstract:Background and Aims The duodenal-jejunal bypass liner (DJBL) is an Endoscopic Device that induces weight loss and improves glycemic control in patients with type 2 diabetes mellitus (T2DM). The aim of the current study was to assess the effects of DJBL explantation on glycemic control and body weight. Methods This prospective, observational study included only patients with T2DM who had the DJBL implanted for at least 6 months and had a follow-up of at least 12 months after explantation. The primary endpoints were changes in glycosylated hemoglobin A 1c (HbA 1c ) and body weight during the 12 months after explantation. Secondary endpoints were changes in fasting plasma glucose, blood pressure, and plasma lipid levels. Results In total, 59 patients completed the 12-month follow-up after explantation. During this period body weight increased by 5.6 (standard deviation, 6.4) kg ( P 1c rose from 65 (SD 17) to 70 (SD 20) mmol/mol ( P P P 1c was significantly higher 12 months after explantation compared with baseline and the mean daily dose of insulin used was comparable, the number of patients on insulin remained significantly lower than before implantation. Conclusions Explantation of the DJBL is associated with weight gain and worsening of glycemic control, although some beneficial effects remained detectable 12 months after explantation. A change in strategy is needed to preserve the beneficial effects of DJBL treatment. (Clinical trial registration number: 746∖100111.)
F Gundling - One of the best experts on this subject based on the ideXlab platform.
-
design of the weight loss endoscopy trial wet a multi center randomized controlled trial comparing weight loss in Endoscopically implanted duodenal jejunal bypass liners vs intragastric balloons vs a sham procedure
BMC Gastroenterology, 2018Co-Authors: M Hollenbach, Christiane Prettin, F Gundling, W Schepp, Jochen Seufert, Jurgen Stein, Thomas Rosch, Jens Aberle, Jurgen Feisthammel, David PetroffAbstract:Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive Endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these Devices has not been undertaken or shown to be superior to a sham procedure. We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in Endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the Devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the Devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated. This trial could help to identify the most effective and safest Endoscopic Device, thus determining the new standard procedure for Endoscopic bariatric treatment. 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).
Jurgen Feisthammel - One of the best experts on this subject based on the ideXlab platform.
-
design of the weight loss endoscopy trial wet a multi center randomized controlled trial comparing weight loss in Endoscopically implanted duodenal jejunal bypass liners vs intragastric balloons vs a sham procedure
BMC Gastroenterology, 2018Co-Authors: M Hollenbach, Christiane Prettin, F Gundling, W Schepp, Jochen Seufert, Jurgen Stein, Thomas Rosch, Jens Aberle, Jurgen Feisthammel, David PetroffAbstract:Obesity is a global problem leading to reduced life expectancy, cardiovascular diseases, diabetes and many types of cancer. Even people willing to accept treatment only achieve a mean weight loss of about 5 kg using commercial weight loss programs. Surgical interventions, e.g. sleeve gastrectomy or gastric bypass are effective but accompanied by risk of serious complications and side effects. Less invasive Endoscopic procedures mainly comprise the intragastric balloon (IB) and the duodenal-jejunal bypass liner (DJBL). To date, a randomized comparison between these Devices has not been undertaken or shown to be superior to a sham procedure. We designed a multi-center, randomized, patient and assessor-blinded, controlled trial comparing weight loss in Endoscopically implanted IB vs. DJBL vs. a sham procedure. A total of 150 patients with a BMI > 35 kg/m2 or > 30 with obesity-related comorbidities and indication for proton pump inhibitors are randomized to receive either IB, DJBL or a sham gastroscopy (2:2:1 ratio). All participants undergo regular dietary consultation. The IB will be removed after 6 months, whereas the DJBL will be explanted after 12 months. All patients will receive gastroscopies at implantation and explantation of the Devices or sedation without gastroscopy to maintain blinding. Main exclusion criteria are malignant diseases, peptic ulcer or previous bariatric intervention. Weight loss 12 months after explantation of the Devices, changes in comorbidities, quality of life, complication rates and safety will be evaluated. This trial could help to identify the most effective and safest Endoscopic Device, thus determining the new standard procedure for Endoscopic bariatric treatment. 16th January 2017. DRKS00011036. Funded by the German Research Foundation (DFG).